University of Hawai‘i at Manoa Homepage

Wei Jia, PhD

Wei Jia, PhD

Wie Jia, PhD
  • Researcher (Professor) and Full Member
    Cancer Epidemiology Program
    University of Hawaii Cancer Center
  • Associate Director for Shared Resources
  • Faculty Director
    Metabolomics Shared Resource

Degrees

  • M.Sc. in Radiopharmaceutical Chemistry, University of Missouri –
    Columbia
  • Ph.D. in Radiopharmaceutical Chemistry, University of Missouri –
    Columbia

Research Focus

Dr. Jia joined the University of Hawaii Cancer Center in 2013 as the Associate Director for Shared Resources. Previously, he spent about 5 years as a Professor at University of North Carolina at Greensboro and Co-Director of UNCG Center for Translational Biomedical Research. Prior to his appointment with UNCG, Dr. Jia worked in China for 10 years, as Professor and Executive Vice Dean at College of Pharmaceutical Science, Tianjin University, and Professor and Vice Dean for Research, School of Pharmacy, Shanghai Jiao Tong University.

Dr. Jia's research interest involves carbon source metabolism and its regulation in cancer cells as well as the molecular mechanisms that link metabolic disruptions in gut microbial-host co-metabolism to metabolic disorders and gastrointestinal cancer. Several research projects are being conducted in Dr. Jia's group to decipher the complex metabolic interactions in gut-liver-brain axis and regulation of cancer cell metabolism.

In addition, Dr. Jia directs a well-recognized metabolomics laboratory (currently as one of the UHCC shared resources). Over the past 13 years, his lab has developed a number of metabolomics technologies and protocols, focusing on the quantitative analysis of endogenous small-molecule metabolites and trace elements from biological specimens including blood, urine, saliva, and tissues of experimental animals and human subjects. Many of these technologies have been applied in clinical and translational research, involving (1) unbiased metabolic profiling and data mining, metabolite annotation and biological interpretation using combined high sensitivity, high throughput LC-MS-MS and GC-MS platforms; (2) targeted and quantitative analysis of metabolic rates and pathways using isotope labeled common substrates such as glucose and cholate; (3) classification and prediction of disease phenotypes based on their unique metabolic signatures and biomarkers for patient stratification and personalized treatment; and (4) novel methodologies to delineate the host-gut microbe co-metabolism of diets and multi-component herbal medicines, such as poly-pharmacokinetics and gut microbial metabolomics.

Selected Publications

  • Chen, WL, Wang, YY, Zhao, AH, Xia, L, Xie, GX, Su, MM, Zhao, LJ, Liu, JJ, Qu, C, Wei, RM, Rajani, C, Ni, Y, Cheng, Z, Chen, Z, Chen, SJ, Jia, W. (2016). Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential, Cancer Cell, 30(5), 779-791, 2016. PMID: 27746145
  • Xie, GX, Wang, XN, Huang, FJ, Zhao, AH, Chen, WL, Yan, JY, Zhang, YJ, Lei, S, Ge, K, Zheng, XJ, Liu, JJ, Su, MM, Liu, P, Jia, W. (2016). Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. International Journal of Cancer, 139(8), 1764-1775. PMID: 27273788
  • Qiu YP, Cai GX, Zhou BS, Li D, Zhao AH, Xie GX, Li HK, Cai SJ, Xie D, Huang CZ, Ge WT, Zhou ZX, Xu L, Jia WP, Zheng S, Yen Y, Jia W. (2014). A distinct metabolic signature of human colorectal cancer with prognostic potential, Clinical Cancer Research, 20(8), 2136-2146. PMID: 24526730
  • Zheng XJ, Zhao AH, Xie GX, Chi Y, Zhao LJ, Li HK, Wang CR, Bao YQ, Jia WP, Luther M, Su MM, Nicholson JK, Jia W. (2013). Melamine-Induced renal toxicity is mediated by the gut microbiota. Science Translational Medicine, 5(172):172ra22. PMID:23408055
  • Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. (2012). Host-gut microbiota metabolic interactions. Science, 336(6086): 1262-7. PMID:22674330
  • Jia W, Li HK, Zhao LP, Nicholson JK. (2008). Gut microbiota: a potential new territory for drug targeting. Nature Reviews Drug Discovery, 7(2):123-9. PMID:18239669

Publication list via PubMed

Active Grants

  • W. Jia, Principal Investigator
    NIH/NCI 1U01CA188387-01A1
    "Gut microbiota mediated bile acid alterations in hepatic carcinogenesis"
    08/01/15 - 07/31/20
  • W. Jia, Co-Investigator (PI: Brouwer)
    NIH/NIGMS 2R01GM041935 - 22 / P140RO
    "Altered hepatic disposition of anionic drugs-mechanisms"
    09/01/14 - 8/31/19
  • W. Jia, Co-Investigator (PI: Holcombe)
    NIH/NCI P30 CA071789
    "Cancer Center Support Grant (CCSG): University of Hawaii Cancer Center"
    07/01/12 – 08/31/17
  • W. Jia, Co-Investigator (PI: Cheng)
    NIH/NCI 1 P01 CA154295-01A1
    "Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy"
    04/01/12 - 03/31/17
  • W. Jia, Principal Investigator
    Nestle Institute of Health Sciences Ltd. Award 007184-00002
    "Microbiome metabonomics: monitoring mammalian - gut microbial co- metabolism in human plasma, urine and stools"
    03/01/15 - 02/28/17